GSH-YCC (discovery cohort) | AMC-SMC (validation cohort) | |||||||
---|---|---|---|---|---|---|---|---|
Variables | Non-complete MRI responders (N = 151) | Complete MRI responders (N = 30) | Total (N = 181) | P value | Non-complete MRI responders (N = 219) | Complete MRI responders (N = 47) | Total (N = 266) | P value |
Age at diagnosis, y | 0.760 | 0.102 | ||||||
< 50 | 100 (66.2) | 19 (63.3) | 119 (65.7) | 88 (40.2) | 25 (53.2) | 113 (42.5) | ||
≥ 50 | 51 (33.8) | 11 (36.7) | 62 (34.3) | 131 (59.8) | 22 (46.8) | 153 (57.5) | ||
Subtype | 0.324 | 0.398 | ||||||
HER2+ | 65 (43.0) | 10 (33.3) | 75 (41.4) | 122 (55.7) | 23 (48.9) | 145 (54.5) | ||
TNBC | 86 (57.0) | 20 (66.7) | 106 (58.6) | 97 (44.3) | 24 (51.1) | 121 (45.5) | ||
Pathologically confirmed lymph nodea | 0.501 | 0.682 | ||||||
Yes | 96 (63.6) | 21 (70.0) | 117 (64.6) | 196 (89.5) | 43 (91.5) | 239 (89.8) | ||
No | 55 (36.4) | 9 (30.0) | 64 (35.4) | 23 (10.5) | 4 (8.5) | 27 (10.2) | ||
Removed lymph nodeb | 16 (10–38) | 13 (10–28) | 15 (10–38) | 0.015 | 10 (5–34) | 10 (5–31) | 10 (5–34) | 0.993 |
Histologic gradec | 0.108 | |||||||
1 or 2 | 68 (62.4) | 14 (82.4) | 82 (65.1) | |||||
3 | 41 (37.6) | 3 (17.6) | 44 (34.9) | |||||
Ki-67a | 0.861 | |||||||
< 14% | 34 (27.9) | 6 (26.1) | 40 (27.6) | |||||
≥ 14% | 88 (72.1) | 17 (73.9) | 105 (72.4) | |||||
Clinical T stage | 0.040 | 0.015 | ||||||
1 | 4 (2.7) | 3 (10.0) | 7 (3.9) | 4 (1.8) | 4 (8.5) | 8 (3.0) | ||
2 | 95 (62.9) | 22 (73.3) | 117 (64.6) | 147 (67.1) | 24 (51.1) | 171 (64.3) | ||
≥ 3 | 52 (34.4) | 5 (16.7) | 57 (31.5) | 68 (31.1) | 19 (40.4) | 87 (32.7) | ||
Clinical N stage | 0.945 | 0.320 | ||||||
1 | 100 (66.2) | 19 (63.3) | 119 (65.7) | 147 (67.1) | 28 (59.6) | 175 (65.8) | ||
2 | 15 (9.9) | 3 (10.0) | 18 (9.9) | 20 (9.1) | 3 (6.4) | 23 (8.6) | ||
3 | 36 (23.8) | 8 (26.7) | 44 (24.3) | 52 (23.7) | 16 (34.0) | 68 (25.6) | ||
Breast operation | 0.042 | 0.095 | ||||||
Breast-conserving surgery | 70 (46.4) | 20 (66.7) | 90 (49.7) | 99 (45.2) | 15 (31.9) | 114 (42.9) | ||
Mastectomy | 81 (53.6) | 10 (33.3) | 91 (50.3) | 120 (54.8) | 32 (68.1) | 152 (57.1) | ||
Neoadjuvant systemic therapy regimen | 0.373 | 0.081 | ||||||
Chemotherapy | 86 (57.0) | 20 (66.7) | 106 (58.6) | 97 (44.3) | 24 (51.1) | 121 (45.5) | ||
Chemotherapy + Trastuzumab | 27 (17.9) | 6 (20.0) | 33 (18.2) | 103 (47.0) | 15 (31.9) | 118 (44.4) | ||
Chemotherapy + Trastuzumab + Pertuzumab | 38 (25.2) | 4 (13.3) | 42 (23.2) | 19 (8.7) | 8 (17.0) | 27 (10.2) |